Protalix BioTherapeutics, Inc.
PLX
Positions held
Your positionsPLX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $217.54M | Enterprise value | $186.09M | Trailing P/E | 11.74 | Forward P/E | 4.35 |
| PEG | — | Price / book | 3.05 | Beta | -0.09 | Dividend yield | 0.00% |
| Revenue growth | 27.1% | Earnings growth | 2241.1% | Gross margin | 45.8% | Operating margin | 23.5% |
| Profit margin | 23.5% | ROE | 31.2% | ROA | 15.4% | Debt / equity | 0.13 |
| Current ratio | 2.94 | Free cash flow | $2.99M | Analyst recommendation | none | Mean target | $11.00 |
| 52w high | $3.19 | 52w low | $1.60 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $19.9M | $33.8M | $9.1M | $17.9M | $15.7M | — |
| Op margin | 23.5% | 62.7% | -51.1% | 11.9% | 7.5% | — |
| Net income | $3.8M | $18.3M | -$5.5M | $2.4M | $0.2M | — |
| Gross margin | 61.0% | 87.8% | 49.4% | 53.4% | 62.5% | — |
| Gross profit | $12.1M | $29.6M | $4.5M | $9.5M | $9.8M | — |
| Operating income | $4.7M | $21.1M | -$4.7M | $2.1M | $1.2M | — |
- Revenue -41% vs prior quarter ($20M vs $34M).
- Gross margin 61% (was 87.8% prior quarter).
- Operating margin compressed to 23.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $52.7M | $53.4M | $65.5M | $47.6M |
| Op margin | -10.4% | 7.3% | 16.0% | -27.3% |
| Net income | -$6.6M | $2.9M | $8.3M | -$14.9M |
| Gross margin | 48.8% | 54.5% | 64.9% | 58.9% |
| Gross profit | $25.8M | $29.1M | $42.5M | $28.0M |
| Operating income | -$5.5M | $3.9M | $10.5M | -$13.0M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-22 · Netflix downgraded, SanDisk initiated: Wall Street's top analyst calls
2026-09-08 · Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences
2026-08-14 · Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary
2026-08-13 · PLX: Elfabrio Estimates Up
2026-08-12 · Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highlights: Net Income Surges to $3. ...
2026-08-12 · Protalix: Q2 Earnings Snapshot
2026-08-12 · Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
2026-08-05 · Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
2026-07-29 · Half-year report on Pluxee N.V.’s liquidity contract as of June 30, 2026
Price (daily)
Full chart · RSI · MACD · patterns